Progyny, Inc. (NASDAQ:PGNY) Stock Position Lowered by Nebula Research & Development LLC

Nebula Research & Development LLC decreased its stake in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) by 52.9% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 41,773 shares of the company's stock after selling 46,849 shares during the period. Nebula Research & Development LLC's holdings in Progyny were worth $721,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Vanguard Group Inc. boosted its position in Progyny by 0.6% during the 4th quarter. Vanguard Group Inc. now owns 8,692,132 shares of the company's stock valued at $149,939,000 after purchasing an additional 48,271 shares during the period. Pacer Advisors Inc. grew its position in shares of Progyny by 47.5% during the fourth quarter. Pacer Advisors Inc. now owns 3,676,200 shares of the company's stock worth $63,414,000 after acquiring an additional 1,183,558 shares during the last quarter. River Road Asset Management LLC acquired a new stake in shares of Progyny in the 4th quarter worth about $25,529,000. Fort Washington Investment Advisors Inc. OH lifted its position in Progyny by 90.1% in the 4th quarter. Fort Washington Investment Advisors Inc. OH now owns 1,467,780 shares of the company's stock valued at $25,319,000 after purchasing an additional 695,740 shares during the last quarter. Finally, Barclays PLC boosted its stake in Progyny by 95.7% during the 4th quarter. Barclays PLC now owns 1,382,205 shares of the company's stock valued at $23,843,000 after purchasing an additional 676,048 shares during the period. 94.93% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on PGNY shares. Bank of America lifted their price target on Progyny from $21.00 to $25.00 and gave the company a "buy" rating in a report on Tuesday, February 11th. JPMorgan Chase & Co. raised their price target on Progyny from $17.00 to $23.00 and gave the company a "neutral" rating in a report on Tuesday, January 28th. Canaccord Genuity Group upped their price objective on shares of Progyny from $17.00 to $23.00 and gave the stock a "hold" rating in a report on Friday, February 28th. Finally, BTIG Research raised shares of Progyny from a "neutral" rating to a "buy" rating and set a $28.00 target price on the stock in a research note on Monday, March 31st. Eight research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $23.64.

Progyny Stock Up 1.9 %

NASDAQ:PGNY traded up $0.43 during trading hours on Friday, reaching $23.23. 721,327 shares of the company's stock were exchanged, compared to its average volume of 1,747,568. The company has a market capitalization of $1.99 billion, a P/E ratio of 40.05, a price-to-earnings-growth ratio of 2.39 and a beta of 1.37. Progyny, Inc. has a 12 month low of $13.39 and a 12 month high of $33.84. The business's 50-day simple moving average is $21.90 and its two-hundred day simple moving average is $19.33.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.